Total syntheses of naamidine G and 14-methoxynaamidine G

Panduka B. Koswatta, Carl J. Lovely *

Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX 76019-0065, United States

A R T I C L E   I N F O

Article history:
Received 24 September 2009
Revised 19 October 2009
Accepted 23 October 2009
Available online 30 October 2009

A B S T R A C T

Simple total syntheses of two *Leucetta*-derived marine alkaloids have been developed using position-specific halogen–metal exchange of polyhaloimidazoles to introduce the benzyl substituted sidechains. Introduction of the C2 amine group by lithiation and trapping with tosyl azide provides amines on catalytic hydrogenation, which can be converted to naamidine G and 14-methoxynaamidine G using a procedure described in the literature.

© 2009 Elsevier Ltd. All rights reserved.

2-Aminoimidazole alkaloids have recently attracted the attention of the synthetic community, in particular several members of the oroidin family of alkaloids.[1,2] A less well-explored group of 2-aminoimidazole-containing natural products are found in sponges of the *Leucettidae* family of sponges. The *Leucetta* family of alkaloids is characterized by the presence of a 2-aminoimidazole moiety which is substituted at various positions around the heterocycle and possesses typically one or two benzylic fragments (**1–6**, Fig. 1).[1b] They range in complexity from the fairly simple clathridine A (**1**)[3] via naamine/naamidine type systems (e.g., naamine D (**2**), naamidine G (**3**), and 14-methoxynaamidine G (**5**))[4] to the more elaborate and highly oxygenated members such as calcaridine A (**4**) and spiroleucettadine (**6**).[5] From a medicinal chemistry perspective, several of these alkaloids have been reported to exhibit activity as antibiotics,[6] nitric oxide synthase inhibitors,[7] and cytotoxicity,[8] but in general their broad scale pharmacological evaluation has not been addressed. Although these molecules are not overly complex or challenging targets, they are potentially attractive scaffolds for evaluation in high-throughput screening programs.[1b]

Our laboratory has developed a number of synthetic methods for the total synthesis of 2-aminoimidazole alkaloids using polyhaloimidazoles as the starting point, utilizing this strategy en route to the total synthesis of members of both the oroidin and *Leucetta* families of alkaloids.[2,9] Following earlier reports,[10] we and others have demonstrated that 4,5-dihaloimidazoles can be functionalized in a sequential and controlled manner in the order of C5→C4→C2 using Grignard reagents (for functionalization at the 4- and 5-positions) and *n*-BuLi (for C2).[9,11,12] This manuscript describes the application of this strategy in the total syntheses of naamidine G (**3**) and 14-methoxynaamidine G (**5**).

Naamidine G (**3**) and 14-methoxynaamidine G (**5**) were isolated and described by Pietra in 1995, but little in terms of biological activity of these natural products was reported.[4b] It is mentioned

that the crude extract possess mild cytotoxicity (against KB cells) and activity against *Candida albicans*, but apparently the purified compounds were not further evaluated.[4b] Our approach to these natural products was patterned after a similar sequence of reactions used en route to calcaridine A[9a] starting from 4,5-diiodo-l-methylimidazole (**7**). Specifically, **7** was converted to the corresponding 4-iodoimidazole **8** by treatment with EtMgBr and then *p*-anisaldehyde (Scheme 1).[9a] After ionic reduction of the ben-


Figure 1. Selected *Leucetta* alkaloids.

* Corresponding author. Tel.: +1 817 272 5446; fax: +1 817 272 3808.
 *E-mail address:* lovely@uta.edu (C.J. Lovely).

Scheme 1. Total synthesis of naamidine G (**3**).

zylic hydroxyl group in **8** with Et$_3$SiH and TFA, the resulting 4-iod-oimidazole was reacted with EtMgBr to effect formation of the imidazol-4-yl Grignard reagent which was treated with *N*-methyl-formanilide (**10**) to provide the aldehyde **11**. Reaction of this alde-hyde with *p*-MeOC$_6$H$_4$MgBr provided the desired alcohol **12**, which is the key intermediate for both naamidine G and 14-meth-oxynaamidine G (Scheme 2). Removal of the doubly benzylic alco-hol in **12** was achieved by reduction with Et$_3$SiH and TFA at room temperature affording **13**. Lithiation at C2 was accomplished with *n*-BuLi and the resulting organolithium species was treated with TsN$_3$ to install an azide moiety, which was subjected to the catalytic hydrogenation to provide 1-methylnaamine D (**15**). This was then converted to naamidine G (**3**) using the procedure reported earlier with TMS-activated methyl parabanic acid[13,9b] to complete the total synthesis of **3** in 41% overall yields in eight steps.

The total synthesis of 14-methoxynaamidine G (**5**) commenced with the conversion of alcohol **12** to methyl ether **16** with methanol and TFA (Scheme 2). Introduction of C2 azide was accomplished by metalation and reaction with TsN$_3$ provided **17**, which was con-verted to amine **18** by catalytic hydrogenation. Following the same reaction as above, TMS-activated methyl parabanic acid provided 14-methoxynaamidine G (**5**) in low yield. Initially it was assumed that the TMS source used (BSA = N,O-bis trimethylsilylacetamide) might cause the decomposition of the starting material. Therefore, the introduction of hydantoin moiety was attempted with other methods reported in the literature.[14] However, these methods failed to give the product and only the decomposition of the starting material was observed. The reason for the low yield from these reactions is still under investigation, but presumably is a result of competitive silylation and ionization of the methyl ether.

The spectroscopic data of the synthetic compounds were in agreement with the data reported for the natural products. However the melting point of the synthetic naamidine G was 195–196 °C in contrast to the natural product (94 °C).[4b]

Scheme 2. Total synthesis of 14-methoxynaamidine G (**5**).

In summary, we have developed high yielding eight-step syntheses of the *Leucetta* alkaloids naamidine G (**3**) and 14-methoxynaamidine G (**5**) using a sequential chemoselective halogen-magnesium exchange, permitting the selective installation of the C5 and C4-benzyl groups without protection of the more acidic C2-position. Subsequent lithiation at C2 and electrophilic trapping leads to introduction 2-amino moiety. We are actively exploring the synthesis of other members of the *Leucetta* family of alkaloids, and their analogs for medicinal chemistry programs.

Acknowledgments

References and notes

1. (a) Arndt, H.-D.; Riedrich, M. *Angew. Chem., Int. Ed.* **2008**, *47*, 4785; (b) Sullivan, J. D.; Giles, R. L.; Looper, R. E. *Curr. Bioact. Compd.* **2009**, *5*, 39; See also: (c) Giles, R. L.; Sullivan, J. D.; Steiner, A. M.; Looper, R. E. *Angew. Chem., Int. Ed.* **2009**, *48*, 3116.
2. He, Y.; Du, H.; Sivappa, R.; Lovely, C. J. *Synlett* **2006**, 965.
3. (a) Ciminiello, P.; Fattorusso, E.; Magno, S.; Mangoni, A. *Tetrahedron* **1989**, *45*, 3873; (b) Ciminiello, P.; Fattorusso, E.; Mangoni, A.; Di Blasio, B.; Pavone, V. *Tetrahedron* **1990**, *46*, 4387.
4. For isolation see: (a) Dunbar, D. C.; Rimoldi, J. M.; Clark, A. M.; Kelly, M.; Hamann, M. T. *Tetrahedron* **2000**, *56*, 8795–8798; (b) Mancini, I.; Guella, G.; Debitus, C.; Pietra, F. *Helv. Chim. Acta* **1995**, *78*, 1178.
5. (a) Edrada, R. A.; Stessman, C. C.; Crews, P. *J. Nat. Prod.* **2003**, *66*, 939; (b) Ralifo, P.; Crews, P. *J. Org. Chem.* **2004**, *69*, 9025; (c) White, K. N.; Amagata, T.; Oliver, A. G.; Tenney, K.; Wenzel, P. J.; Crews, P. *J. Org. Chem.* **2008**, *73*, 8719.
6. Akee, R.; Carroll, T. R.; Yoshida, W. Y.; Scheuer, P. J.; Stout, T. J.; Clardy, J. *J. Org. Chem.* **1990**, *55*, 1944.
7. Dunbar, D. C.; Rimoldi, J. M.; Clark, A. M.; Kelly, M.; Hamann, M. T. *Tetrahedron* **2000**, *56*, 8795.
8. (a) Copp, B. R.; Fairchild, C. R.; Cornell, L.; Casazza, A. M.; Robinson, S.; Ireland, C. M. *J. Med. Chem.* **1998**, *41*, 3909; (b) Aberle, N. S.; Catimel, J.; Nice, E. C.; Watson, K. G. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3741.
9. (a) Koswatta, P. B.; Sivappa, R.; Dias, H. V.; Lovely, C. J. *Org. Lett.* **2008**, *10*, 5055–5058; (b) Koswatta, P. B.; Lovely, C. J. *Tetrahedron Lett.* **2009**, *50*, 4998; (c) Koswatta, P. B.; Sivappa, R.; Dias, H. V. R.; Lovely, C. J. *Synthesis* **2009**, *13*, 2970.
10. Carver, D. S.; Lindell, S. D.; Saville-Stones, E. A. *Tetrahedron* **1997**, *53*, 14481.
11. (a) Lovely, C. J.; Du, H.; Sivappa, R.; Bhandari, M. K.; He, Y.; Dias, H. V. R. *J. Org. Chem.* **2007**, *72*, 3741; (b) Bhandari, M. R.; Sivappa, R.; Lovely, C. J. *Org. Lett.* **2009**, *11*, 1535.
12. (a) Dehmel, F.; Abarbri, M.; Knochel, P. *Synlett* **2000**, 345; (b) Abarbri, M.; Thibonnet, J.; Bérillon, L.; Dehmel, F.; Rottländer, M.; Knochel, P. *J. Org. Chem.* **2000**, *65*, 4618; (c) Knochel, P.; Dohle, W.; Gommermann, N.; Kneisel, F.; Kopp, F.; Korn, T.; Sapountzis, I.; Vu, V. *Angew. Chem., Int. Ed.* **2003**, *42*, 4302; (d) Yang, X.; Knochel, P. *Chem. Commun.* **2006**, 2170.
13. Aberle, N. S.; Lessene, G.; Watson, K. G. *Org. Lett.* **2006**, *8*, 419.
14. (a) Kawasaki, I.; Taguchi, N.; Yoneda, Y.; Yamashita, M.; Ohta, S. *Heterocycles* **1996**, *43*, 1375; (b) Ohta, S.; Tsuno, N.; Maeda, K.; Nakamura, S.; Taguchi, N.; Yamashita, M.; Kawasaki, I. *Tetrahedron Lett.* **2000**, *41*, 4623; (c) Nakamura, S.; Kawasaki, I.; Yamashita, M.; Ohta, S. *Heterocycles* **2003**, *60*, 583.